With 100% of patients achieving a best PSA50 decline, how significant is this outcome for heavily pre-treated 5L mCRPC patients, and what does it imply about JANX007’s activity as a tumor-activated T cell engager?

The study highlighted that 75% of patients maintained PSA50 declines for 12 weeks or longer. How critical is this durability for patients, and how does it compare to other available or emerging treatments in this space?

Among the study cohort, 63% achieved PSA90 declines, and 31% achieved PSA99 declines. How meaningful are these deep PSA responses in predicting long-term outcomes such as progression-free survival or overall survival?

The interim data reported a 50% overall response rate (ORR) and a 63% disease control rate (DCR). How does this anti-tumor activity position JANX007 among current and experimental therapies for mCRPC?

With cytokine release syndrome (CRS) and treatment-related adverse events (TRAEs) primarily limited to cycle 1 and grades 1 or 2, what does this favorable safety profile mean for potential long-term administration of JANX007?

Given the strong clinical activity observed in 5L patients, how could JANX007’s efficacy translate to earlier lines of therapy, and what unmet needs might it address in pre-PLUVICTO® 2L/3L populations?

The results showed that PSA responses were observed irrespective of resistance driver aberrations or prior taxane or ARPi therapies. How does this versatility enhance JANX007’s potential use in broader patient populations?

With two once-weekly dose regimens selected for Phase 1b expansion trials, what key outcomes should be prioritized to establish JANX007 as a viable treatment option for mCRPC, and what updates can we expect in 2025?